Dr Ray O’Connor continues his look at recent clinical articles on therapeutics, with an emphasis on antibiotics, postbiotics, and faecal transplantation ...

Morning nasal congestion can signal allergies, sinusitis, dry air, GERD, or structural nasal issues. ENT experts say that ...

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes ...

It's one of the most common nasal complaints and while often harmless, it can be maddening and affect sleep, focus and even ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission - ...

Congestion - that bunged up, stuffy nose ­feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for ...